Literature DB >> 27815661

Improved Radiosynthesis and Biological Evaluations of L- and D-1-[18F]Fluoroethyl-Tryptophan for PET Imaging of IDO-Mediated Kynurenine Pathway of Tryptophan Metabolism.

Yangchun Xin1, Hancheng Cai2,3.   

Abstract

PURPOSE: Tryptophan metabolism via indoleamine 2,3-dioxygenase (IDO)-mediated kynurenine pathway plays a role in immunomodulation and has been emerging as a plausible target for cancer immunotherapy. Imaging IDO-mediated kynurenine pathway of tryptophan metabolism with positron emission tomography (PET) could provide valuable information for noninvasive assessment of cancer immunotherapy response. In this work, radiotracer 1-(2-[18F]fluoroethyl)-L-tryptophan (1-L-[18F]FETrp) and its enantioisomer 1-D-[18F]FETrp were synthesized and evaluated for PET imaging of IDO-mediated kynurenine pathway of tryptophan metabolism. PROCEDURES: Enantiopure 1-L-[18F]FETrp and 1-D-[18F]FETrp were prepared by a nucleophilic reaction of N-boc-1-(2-tosylethyl) tryptophan tert-butyl ester with [18F]Fluoride, followed by acid hydrolysis in a GE Tracerlab FX-N module. In vitro cell uptake assays were performed with a breast cancer cell line MDA-MB-231. Small animal PET/computed tomography (CT) imaging was carried out in a mouse model bearing MDA-MB-231 xenografts.
RESULTS: Automatic radiosynthesis of 1-L-[18F]FETrp and 1-D-[18F]FETrp was achieved by a one-pot two-step approach in 19.0 ± 7.0 and 9.0 ± 3.0 % (n = 3) decay-corrected yield with radiochemical purity over 99 %, respectively. In vitro cell uptake study indicated the uptake of 1-D-[18F]FETrp in MDA-MB-231 cells was 0.73 ± 0.07 %/mg of protein at 60 min, while, the corresponding uptake of 1-L-[18F]FETrp was 6.60 ± 0.77 %/mg. Further mechanistic assays revealed that amino acid transport systems L-tpye amino acid transporter (LAT) and alanine-, serine-, and cysteine-preferring (ASC), and enzyme IDO expression were involved in cell uptake of 1-L-[18F]FETrp. Small animal PET/CT imaging study showed the tumor uptake of 1-L-[18F]FETrp was 4.6 ± 0.4 % ID/g, while, the tumor uptake of 1-D-[18F]FETrp was low to 1.0 ± 0.2 % ID/g, which were confirmed by ex vivo biodistribution study.
CONCLUSIONS: We have developed a practical method for the automatic radiosynthesis of 1-L-[18F]FETrp and 1-D-[18F]FETrp. Our biological evaluation results suggest that 1-L-[18F]FETrp is a promising radiotracer for PET imaging of IDO-mediated kynurenine pathway of tryptophan metabolism in cancer.

Entities:  

Keywords:  Cancer; IDO; Kynurenine pathway; PET imaging; Radiosynthesis; Tryptophan metabolism

Mesh:

Substances:

Year:  2017        PMID: 27815661     DOI: 10.1007/s11307-016-1024-z

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  28 in total

Review 1.  Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy.

Authors:  Seth A Wander; Bryan T Hennessy; Joyce M Slingerland
Journal:  J Clin Invest       Date:  2011-04-01       Impact factor: 14.808

2.  Tryptophan metabolism in breast cancers: molecular imaging and immunohistochemistry studies.

Authors:  Csaba Juhász; Zeina Nahleh; Ian Zitron; Diane C Chugani; Majid Z Janabi; Sudeshna Bandyopadhyay; Rouba Ali-Fehmi; Thomas J Mangner; Pulak K Chakraborty; Sandeep Mittal; Otto Muzik
Journal:  Nucl Med Biol       Date:  2012-03-22       Impact factor: 2.408

Review 3.  L-type amino acid transport and cancer: targeting the mTORC1 pathway to inhibit neoplasia.

Authors:  Qian Wang; Jeff Holst
Journal:  Am J Cancer Res       Date:  2015-03-15       Impact factor: 6.166

Review 4.  Kynurenines in the CNS: recent advances and new questions.

Authors:  László Vécsei; Levente Szalárdy; Ferenc Fülöp; József Toldi
Journal:  Nat Rev Drug Discov       Date:  2012-12-14       Impact factor: 84.694

5.  Design and automated production of 11C-alpha-methyl-l-tryptophan (11C-AMT).

Authors:  Xuan Huang; Xia Xiao; Robert J Gillies; Haibin Tian
Journal:  Nucl Med Biol       Date:  2016-02-24       Impact factor: 2.408

6.  Evaluation of D-isomers of O-11C-methyl tyrosine and O-18F-fluoromethyl tyrosine as tumor-imaging agents in tumor-bearing mice: comparison with L- and D-11C-methionine.

Authors:  Hideo Tsukada; Kengo Sato; Dai Fukumoto; Shingo Nishiyama; Norihiro Harada; Takeharu Kakiuchi
Journal:  J Nucl Med       Date:  2006-04       Impact factor: 10.057

7.  Preferred stereoselective transport of the D-isomer of cis-4-[18F]fluoro-proline at the blood-brain barrier.

Authors:  Karl-Josef Langen; Kurt Hamacher; Dagmar Bauer; Stefan Bröer; Dirk Pauleit; Hans Herzog; Frank Floeth; Karl Zilles; Heinz H Coenen
Journal:  J Cereb Blood Flow Metab       Date:  2005-05       Impact factor: 6.200

8.  Synthesis and biological evaluation of ¹⁸F-labeled fluoropropyl tryptophan analogs as potential PET probes for tumor imaging.

Authors:  Aristeidis Chiotellis; Linjing Mu; Adrienne Müller; Svetlana V Selivanova; Claudia Keller; Roger Schibli; Stefanie D Krämer; Simon M Ametamey
Journal:  Eur J Med Chem       Date:  2013-10-30       Impact factor: 6.514

9.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.

Authors:  Catherine Uyttenhove; Luc Pilotte; Ivan Théate; Vincent Stroobant; Didier Colau; Nicolas Parmentier; Thierry Boon; Benoît J Van den Eynde
Journal:  Nat Med       Date:  2003-09-21       Impact factor: 53.440

Review 10.  IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance.

Authors:  David H Munn; Andrew L Mellor
Journal:  Trends Immunol       Date:  2016-01-31       Impact factor: 16.687

View more
  15 in total

Review 1.  PET and SPECT imaging of melanoma: the state of the art.

Authors:  Weijun Wei; Emily B Ehlerding; Xiaoli Lan; Quanyong Luo; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-30       Impact factor: 9.236

Review 2.  Utility of MRI, PET, and ictal SPECT in presurgical evaluation of non-lesional pediatric epilepsy.

Authors:  Csaba Juhász; Flóra John
Journal:  Seizure       Date:  2019-05-11       Impact factor: 3.184

3.  Evaluation of L-1-[18F]Fluoroethyl-Tryptophan for PET Imaging of Cancer.

Authors:  Yangchun Xin; Xiaofei Gao; Li Liu; Woo-Ping Ge; Manoj K Jain; Hancheng Cai
Journal:  Mol Imaging Biol       Date:  2019-12       Impact factor: 3.488

4.  Fluorine-18-Labeled PET Radiotracers for Imaging Tryptophan Uptake and Metabolism: a Systematic Review.

Authors:  Flóra John; Otto Muzik; Sandeep Mittal; Csaba Juhász
Journal:  Mol Imaging Biol       Date:  2020-08       Impact factor: 3.488

Review 5.  Amino Acid Metabolism as a Target for Breast Cancer Imaging.

Authors:  Gary A Ulaner; David M Schuster
Journal:  PET Clin       Date:  2018-07

6.  Evaluation of radiofluorinated carboximidamides as potential IDO-targeted PET tracers for cancer imaging.

Authors:  Xuan Huang; Zhongjie Pan; Michael L Doligalski; Xia Xiao; Epifanio Ruiz; Mikalai M Budzevich; Haibin Tian
Journal:  Oncotarget       Date:  2017-07-18

7.  Synthesis of 5-[18F]Fluoro-α-methyl Tryptophan: New Trp Based PET Agents.

Authors:  Benjamin C Giglio; Haiyang Fei; Mengzhe Wang; Hui Wang; Liu He; Huijuan Feng; Zhanhong Wu; Hongjian Lu; Zibo Li
Journal:  Theranostics       Date:  2017-04-07       Impact factor: 11.556

Review 8.  The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy.

Authors:  Lilla Hornyák; Nikoletta Dobos; Gábor Koncz; Zsolt Karányi; Dénes Páll; Zoltán Szabó; Gábor Halmos; Lóránt Székvölgyi
Journal:  Front Immunol       Date:  2018-01-31       Impact factor: 7.561

Review 9.  IDO1 in cancer: a Gemini of immune checkpoints.

Authors:  Lijie Zhai; Erik Ladomersky; Alicia Lenzen; Brenda Nguyen; Ricky Patel; Kristen L Lauing; Meijing Wu; Derek A Wainwright
Journal:  Cell Mol Immunol       Date:  2018-01-29       Impact factor: 11.530

10.  Off-tumor IDO1 target engagements determine the cancer-immune set point and predict the immunotherapeutic efficacy.

Authors:  Lin Xie; Kuan Hu; Yanhong Duo; Takashi Shimokawa; Katsushi Kumata; Yiding Zhang; Cuiping Jiang; Lulu Zhang; Nobuki Nengaki; Hidekatsu Wakizaka; Yihai Cao; Ming-Rong Zhang
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.